Rami Doukky to Adenosine A2 Receptor Agonists
This is a "connection" page, showing publications Rami Doukky has written about Adenosine A2 Receptor Agonists.
Connection Strength
4.016
-
Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm. J Nucl Cardiol. 2021 06; 28(3):967-977.
Score: 0.660
-
Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging. J Nucl Cardiol. 2020 10; 27(5):1521-1532.
Score: 0.625
-
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
Score: 0.577
-
Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
Score: 0.484
-
Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014; 9:129-37.
Score: 0.455
-
Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
Score: 0.448
-
Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
Score: 0.422
-
Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging. J Nucl Cardiol. 2015 Aug; 22(4):700-13.
Score: 0.124
-
The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
Score: 0.114
-
The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013 Apr; 20(2):205-13.
Score: 0.105